An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
RenovoRx, a biopharmaceutical company listed on Nasdaq under the symbol RNXT, will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Shaun Bagai is scheduled to present on September 12 at 7:00 a.m. ET, discussing the challenges in treating pancreatic tumors and the innovative RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy. One-on-one meetings will also be held with investors.
RenovoRx’s lead product, RenovoGem™, is under Phase 3 study for locally advanced pancreatic cancer.
Positive
None.
Negative
None.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform, today announced management’s participation in the upcoming H.C. Wainwright 24th Annual Global Investment Conference. This conference is to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
Shaun Bagai, RenovoRx’s CEO, will provide a corporate update during his presentation. He will also discuss current available treatment options for pancreatic tumors, why they can fall short of providing an effective solution for treating this deadly disease, and how RenovoRx’s therapy platform re-envisions the treatment of pancreatic and other difficult-to-treat cancers. During the Conference, Shaun will participate in one-on-one meetings with the investment community. Attendees include public companies, and institutional and private investors. To schedule a meeting, please reach out to your H.C. Wainwright representative or send an email to KCSA Strategic Communications at RenovoRx@KCSA.com.
H.C. Wainwright Global Investment Conference Title: A Late-Stage Biopharmaceutical Company with an Innovative Therapy for Targeted Treatment Of Difficult-to-Treat Cancer Format and Dates: Hybrid, September 12-14, 2022 Location:Lotte New York Palace Hotel, New York, New York Presenter:Shaun Bagai, CEO
Presentation Date and Time:Monday, September 12th at 7:00 a.m. ET Webcast:https://journey.ct.events/view/201f5839-590d-40ea-af26-54bfb6f15ae6
Replay Available: A recording of the event will be posted to RenovoRx Website Events page for 90 days after the event
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGem™, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
Company Contact:
RenovoRx, Inc. Shaun R. Bagai, CEO
James Ahlers, CFO
Investor Contact:
KCSA Strategic Communications Valter Pinto or Jack Perkins T:212-896-1254
renovorx@kcsa.com
Media Contact:
Knight Marketing Communications, Ltd. Kevin Knight T: 206-451-4823
kknightpr@gmail.com
Source: RenovoRx, Inc.
FAQ
What is the focus of RenovoRx's therapy platform as mentioned in the press release?
RenovoRx's therapy platform focuses on the localized treatment of difficult-to-treat solid tumors, specifically using the RenovoTAMP™ technology.
When and where is the H.C. Wainwright 24th Annual Global Investment Conference taking place?
The H.C. Wainwright 24th Annual Global Investment Conference will be held from September 12-14, 2022, at the Lotte New York Palace Hotel in New York City.
Who will present at the H.C. Wainwright conference for RenovoRx?
CEO Shaun Bagai will present on behalf of RenovoRx at the conference.
What is the lead product candidate of RenovoRx and its indication?
RenovoRx's lead product candidate is RenovoGem™, indicated for the treatment of unresectable locally advanced pancreatic cancer.
What is the date and time of Shaun Bagai's presentation at the conference?
Shaun Bagai's presentation is scheduled for September 12, 2022, at 7:00 a.m. ET.
